Table 2 Adverse events reported by ≥30% of patients overall, by maximum reported grade
Evaluable patients, n (%) | |||||
|---|---|---|---|---|---|
Cohort 1 | Cohort 2 | Overall | |||
(n = 9) | (n = 10) | (n = 19) | |||
Grade 1/2 | Grade ≥3 | Grade 1/2 | Grade ≥3 | ||
Diarrhea | 6 (67) | 0 | 6 (60) | 0 | 12 (63) |
Nausea | 5 (56) | 0 | 6 (60) | 0 | 11 (58) |
Neutropenia | 3 (33) | 4 (44)a | 2 (20) | 2 (20)b | 11 (58) |
Alopecia | 6 (67) | 0 | 4 (40) | 0 | 10 (53) |
Fatigue | 6 (67) | 0 | 3 (30) | 1 (10) | 10 (53) |
Anemia | 3 (33) | 2 (22) | 1 (10) | 0 | 6 (32) |
Constipation | 4 (44) | 0 | 2 (20) | 0 | 6 (32) |
Peripheral neuropathy | 3 (33) | 0 | 3 (30) | 0 | 6 (32) |
Rash | 1 (11) | 0 | 5 (50) | 0 | 6 (32) |
Vomiting | 3 (33) | 0 | 3 (30) | 0 | 6 (32) |